Introductory remarks

Professor Laura JV Piddock, Director of Scientific Affairs, Global Antibiotic Research & Development Partnership (GARDP) - View Bio

The politics of drug development

Dame Sally Davies, UK Government Special Envoy on Antimicrobial Resistance, UK Department of Health and Social Care

Q&A

In vitro and in vivo profiling of natural products from Myxobacteria towards the development of anti-infective drugs

Dr Jennifer Herrmann, Scientist, HIPS/HZI & DZIF

Gram-negative antibacterial discovery - looking for the high-hanging fruits

Dr Benjamin Blasco Discovery Senior Project Manager, GARDP

Microbial natural products: still an untapped source for novel antibiotic discovery

Dr Olga Genilloud, Scientific Director, Fundación MEDINA

Q&A

From old drugs to new: Repurposing old antibiotics to combat antimicrobial resistance

Dr Christopher Darlow, MRC Clinical Research Fellow, Institute of Systems, Molecular & Integrative Biology, University of Liverpool

Linking PK and PD studies in animals with PBPK/PD modelling – in silico from mouse to human

Dr Katharina Rox, Postdoc, HZI/DZIF

Pre-clinical development of Corallopyronin A – a novel natural product active against helminths, STIs and Staphylococci

Professor Achim Hoerauf, Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn/DZIF

Q&A

Clinical outcomes in Carbapenem resistant Enterobacteriaceae infections treated with Ceftazidime-avibactam: A single centre observational study

Balram Rathish, Clinical Fellow in Infectious Diseases, Aster Medcity, Kochi, India

5-Fluorouracil – mechanism of action and resistance mechanisms

Sara Henderson , Research associate, Norwich Medical School, UEA, UK

Worse than a stroke? Long-term outcome and risk factors for late mortality in Gram-negative bacteraemia

Ioannis Baltas, Foundation Year 3 Doctor, Frimley Health NHS Foundation Trust, UK

Genomic and Bioassay-guided Approaches for Discovery of Novel Antibiotics from Marine Bacteria

Matthias Agbo, University of Nigeria, Nsukka

Epigenetic Mode of Bacterial Drug Resistance

Guru Prasad Manderwad, Kamineni Academy of Medical Sciences and Research Centre

Ecm16 protein confers resistance against the DNA intercalator antibiotic echinomycin

Priyanka Gade, University of Texas at El Paso

Genomic analysis of Colistin resistance in Carbapenem-Resistant Enterobacterales and XDR Klebsiella pneumoniae

Raunak Bir, Senior Resident Doctor, All India Institute of Medical Sciences, New Delhi, India

Formulation, Characterization and Evaluation of Wog19-Loaded and Wog19 +Chloroquine-Loaded Solid Lipid Nanoparticles for the Treatment of Malaria Caused by Sensitive and Resistant Strains of P. berghei

Samuel Uzondu, Lecturer /Researcher, NanoMalaria Research Unit, Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka

The Three Ages of Antibiotics

Emily Mayhew, Historian in residence, Dept of Bioengineering, Imperial College London

Q&A

Day one closing remarks

Professor William Hope, University of Liverpool

Introductory remarks

Professor William Hope, University of Liverpool

Lessons for Clinical Research from COVID-19

Professor Andy Ustianowski, Principal Clinical Research Lead, North Manchester General Hospital

Innovative design of clinical trials

Professor Sarah Walker, University College London

Developing a TB drug in academia: The BTZ043 from lead candidate to pivotal clinical trials – lesson learned from a complex endeavour

Professor Dr Michael Hoelscher, Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich

Q&A

The non-traditional treatment pipeline

Dr Ursula Theuretzbacher, Founder, Center for Anti-Infective Agents (CEFAIA)

Elastase inhibitor

Dr Martin Everett, Chief Scientific Officer, Antabio

Therapeutic Development of Bacteriophages

Professor Martha Clokie, Professor of Microbiology, University of Leicester

Q&A

Facilitators and barriers to securing access to new and old antibiotics

Dr Christine Ardal, Senior Advisor, Institute of Public Health, Norway

Q&A

Careers in Drug Development and Antimicrobial Chemotherapy

Dr Olga Genilloud, Scientific Director, Fundación MEDINA

Dr Sumathi Nambiar, Director, Division of Anti-Infective (DAI), FDA

Prof Dr Rolf Müller, Head of Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) & Department Microbial Natural Products (MINS), Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)

Dr Martin Everett, Chief Scientific Officer, Antabio

Closing remarks

Professor Laura Piddock, Director of Scientific Affairs, GARDP